Annals of Dermatology最新文献

{"title":"Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study).","authors":"Dong Hyun Kim,&nbsp;Sang Wook Son,&nbsp;Ki-Heon Jeong,&nbsp;Jiyoung Ahn,&nbsp;Eun-So Lee,&nbsp;Il-Hwan Kim,&nbsp;Un Ha Lee,&nbsp;Hai-Jin Park,&nbsp;Joo Yeon Ko,&nbsp;Byung-Soo Kim,&nbsp;Jin Ju Kim,&nbsp;Javed Rashid,&nbsp;Kwang Joong Kim","doi":"10.5021/ad.22.041","DOIUrl":"https://doi.org/10.5021/ad.22.041","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations.</p><p><strong>Objective: </strong>To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis.</p><p><strong>Methods: </strong>This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM.</p><p><strong>Results: </strong>Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (<i>p</i>=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted.</p><p><strong>Conclusion: </strong>Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083).</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"107-115"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/e5/ad-35-107.PMC10112372.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Cowden Syndrome Presenting with Diverse Cutaneous Manifestations.","authors":"Jongeun Lee,&nbsp;Dong Min Shin,&nbsp;Se Jin Oh,&nbsp;Ji-Hye Park,&nbsp;Dongyoun Lee","doi":"10.5021/ad.20.265","DOIUrl":"https://doi.org/10.5021/ad.20.265","url":null,"abstract":"<p><p>Cowden syndrome is caused by mutations in the phosphatase and tensin homolog (PTEN) gene and is part of the PTEN hamartoma tumor syndrome. Skin lesions including trichilemmomas, acral keratosis, mucocunateous neuromas and oral paillomas are the most prevalent feature found in patients with Cowden syndrome. It also possesses an increased risk of developing malignancies including breast, thyroid, endometrial, and colorectal cancers. Due to the increased risk of cancer, early diagnosis and regular surveillance are important for Cowden syndrome patients. Herein, we report a case of Cowden syndrome with diverse cutaneous manifestations and thyroid cancer.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"146-150"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/ed/ad-35-146.PMC10112363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription Patterns of Topical Medications in Patients with Atopic Dermatitis: An Investigative Review Using Big Data from the National Health Insurance Corporation.","authors":"Jungsoo Lee,&nbsp;Taeyeong Kim,&nbsp;Sang-Jin Cheon,&nbsp;Jinmi Kim,&nbsp;Hoon-Soo Kim,&nbsp;Byung-Soo Kim,&nbsp;Moon-Bum Kim,&nbsp;Hyun-Chang Ko","doi":"10.5021/ad.22.114","DOIUrl":"https://doi.org/10.5021/ad.22.114","url":null,"abstract":"<p><strong>Background: </strong>Topical medications play a crucial role in the treatment of atopic dermatitis (AD). Topical corticosteroids (TCSs) remain the main treatment of choice and topical antibiotics have also been used. However, with the new topical calcineurin inhibitors (TCIs), the prescription patterns of topical agents have changed over time.</p><p><strong>Objective: </strong>To characterize the prescription patterns of topical medications in Korean patients with AD.</p><p><strong>Methods: </strong>We investigated topical medications prescribed to Korean patients with AD using the National Health Insurance Sharing System (NHISS) database over a 14-year period (2002~2015). Additionally, the potency of prescribed TCSs was compared with AD and psoriasis patients.</p><p><strong>Results: </strong>The annual prescription of TCSs showed a slightly decreasing trend without significant change. In particular, in terms of steroid class, prescription of moderate-to-low potency TCSs were increased and the use of high potency TCSs were decreased. TCSs were the most commonly prescribed topical medications for AD. Tertiary hospitals had a higher prescription rate for TCIs than secondary or primary hospitals (16.2%, 3.1%, and 1.9%, respectively). Additionally, dermatologists prescribed TCIs more frequently than pediatricians and internists (4.3%, 1.2%, and 0.6%, respectively). Among TCSs, Class 5 was prescribed the most (40.6%) followed by Class 7, 6, 4, 3, 1, and 2. When we compared the potency of TCSs prescribed for AD with psoriasis patients, moderate-to-low-potency TCSs were more commonly prescribed in AD.</p><p><strong>Conclusion: </strong>Prescription patterns of topical medications had changed from 2002 to 2015 and differed according to the type of institution and specialty of the physician.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"124-131"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/de/ad-35-124.PMC10112370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9324265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitavastatin Induces Apoptosis of Cutaneous Squamous Cell Carcinoma Cells through Geranylgeranyl Pyrophosphate-Dependent c-Jun N-Terminal Kinase Activation.","authors":"Kyung-Il Kim,&nbsp;Seung-Mee Kim,&nbsp;Young-Yoon Lee,&nbsp;Young Lee,&nbsp;Chang-Deok Kim,&nbsp;Tae-Jin Yoon","doi":"10.5021/ad.22.139","DOIUrl":"https://doi.org/10.5021/ad.22.139","url":null,"abstract":"<p><strong>Background: </strong>Pitavastatin is a cholesterol-lowering drug and is widely used clinically. In addition to this effect, pitavastatin has shown the potential to induce apoptosis in cutaneous squamous cell carcinoma (SCC) cells.</p><p><strong>Objective: </strong>The purpose of this study is to investigate the effects and possible action mechanisms of pitavastatin.</p><p><strong>Methods: </strong>SCC cells (SCC12 and SCC13 cells) were treated with pitavastatin, and induction of apoptosis was confirmed by Western blot. To examine whether pitavastatin-induced apoptosis is related to a decrease in the amount of intermediate mediators in the cholesterol synthesis pathway, the changes in pitavastatin-induced apoptosis after supplementation with mevalonate, squalene, geranylgeranyl pyrophosphate (GGPP) and dolichol were investigated.</p><p><strong>Results: </strong>Pitavastatin dose-dependently induced apoptosis of cutaneous SCC cells, but the viability of normal keratinocytes was not affected by pitavastatin at the same concentrations. In supplementation experiments, pitavastatin-induced apoptosis was inhibited by the addition of mevalonate or downstream metabolite GGPP. As a result of examining the effect on intracellular signaling, pitavastatin decreased Yes1 associated transcriptional regulator and Ras homolog family member A and increased Rac family small GTPase 1 and c-Jun N-terminal kinase (JNK) activity. All these effects of pitavastatin on signaling molecules were restored when supplemented with either mevalonate or GGPP. Furthermore, pitavastatin-induced apoptosis of cutaneous SCC cells was inhibited by a JNK inhibitor.</p><p><strong>Conclusion: </strong>These results suggest that pitavastatin induces apoptosis of cutaneous SCC cells through GGPP-dependent JNK activation.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"116-123"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/f2/ad-35-116.PMC10112368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9324267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data.","authors":"Ji-In Seo,&nbsp;Min-Kyung Shin,&nbsp;Ki-Heon Jeong","doi":"10.5021/ad.20.327","DOIUrl":"https://doi.org/10.5021/ad.20.327","url":null,"abstract":"","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"158-160"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/d0/ad-35-158.PMC10112366.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients.","authors":"Catherine Zilberg,&nbsp;James Guy Lyons,&nbsp;Ruta Gupta,&nbsp;Angela Ferguson,&nbsp;Diona Lee Damian","doi":"10.5021/ad.22.175","DOIUrl":"https://doi.org/10.5021/ad.22.175","url":null,"abstract":"<p><p>Cutaneous squamous cell carcinoma (cSCC) is the most common malignancy in immune-suppressed organ transplant recipients (OTRs). Whilst rates of other malignancies (both cutaneous and non-cutaneous) are elevated in this population, the increase is far less striking. This suggests that cSCC must be a highly immunogenic tumor. The tumor immune microenvironment is altered in cSCC from OTRs. It has reduced anti-tumor properties and instead provides an environment that facilitates tumor growth and survival. Understanding the composition and function of the tumor immune microenvironment in cSCC from OTRs is useful for prognostication and therapeutic decisions.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"91-99"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/05/ad-35-91.PMC10112371.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9324266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Juvenile Patient with LEOPARD Syndrome: Clinical Profile of a Genetically Confirmed Case.","authors":"Pengjie Wan,&nbsp;Ying Cheng,&nbsp;Zhuo Chen,&nbsp;Ji Chen","doi":"10.5021/ad.20.300","DOIUrl":"https://doi.org/10.5021/ad.20.300","url":null,"abstract":"","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"162-164"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/01/ad-35-162.PMC10112373.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9700874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Psoriasis for Initiation of Biologic Therapy: A Cluster Analysis.","authors":"Yul Hee Kim,&nbsp;Seung Il Kim,&nbsp;Bumhee Park,&nbsp;Eun-So Lee","doi":"10.5021/ad.22.148","DOIUrl":"https://doi.org/10.5021/ad.22.148","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a complex and heterogeneous disease that widely affects a patient's life. Biological therapy is usually prescribed in patients with severe psoriasis that do not respond to conventional treatment. However, data on the specific patient characteristics receiving biologics are still unavailable.</p><p><strong>Objective: </strong>To classify patients with psoriasis into subgroups with distinct phenotypes through cluster analysis, and to evaluate the differences between the clusters to predict disease prognosis by examining the response to biological therapy.</p><p><strong>Methods: </strong>The clinical characteristics of the patients with psoriasis were investigated and categorized using hierarchical cluster analysis. After clustering, the clinical characteristics of the patients were compared and the initiation of treatment with biologics according to the clusters were evaluated.</p><p><strong>Results: </strong>A total of 361 patients with psoriasis were classified into two clusters using 16 distinct clinical phenotypes. Group 1 (n=202) consisted of male smokers and alcohol users with higher psoriasis area and severity index (PASI), older age of onset, higher body mass index, and comorbidities including psoriatic arthritis, hypertension, and diabetes when compared to group 2 (n=159). Group 1 had a significantly higher probability of biological treatment initiation than group 2 (<i>p</i>=0.039). The measured risk factors for the initiation of biologics compared were PASI (<i>p</i><0.001) and nail involvement (<i>p</i>=0.022).</p><p><strong>Conclusion: </strong>Cluster analysis classified patients with psoriasis into two subgroups according to their clinical characteristics. Predicting the disease prognosis using a combination of specific clinical parameters may aid in the management of the disease.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"132-139"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/ae/ad-35-132.PMC10112364.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9324268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Various Applications of Purse-String Suture and Its Cosmetic Outcome in Cutaneous Surgical Defects.","authors":"Sujin Park,&nbsp;Yeongjoo Oh,&nbsp;Jong Won Lee,&nbsp;Sooyie Choi,&nbsp;Kyoung Ae Nam,&nbsp;Mi Ryung Roh,&nbsp;Kee Yang Chung","doi":"10.5021/ad.21.263","DOIUrl":"https://doi.org/10.5021/ad.21.263","url":null,"abstract":"<p><strong>Background: </strong>Purse-string suture is a simple technique to reduce wound size and to achieve complete or partial closure of skin defects.</p><p><strong>Objective: </strong>To classify situations in which purse-string sutures can be utilized and to assess the long-term size reduction and cosmetic outcome of the final scar.</p><p><strong>Methods: </strong>Patients (93 from Severance hospital and 12 from Gangnam Severance hospital) in whom purse-string sutures were used between January 2015 and December 2019 were retrospectively reviewed. Wound site, final reconstruction method, repair duration, final wound size, and Vancouver scar scale were assessed.</p><p><strong>Results: </strong>A total of 105 patients were reviewed. Lesions were located on the trunk (48 [45.7%]), limbs (32 [30.5%]), and face (25 [23.8%]). Mean ratio of wound length/primary defect length was 0.79±0.30. Multilayered purse-string suture showed the shortest duration from excision to final repair (<i>p</i><0.001) and most effectively minimized the scar size (scar to defect size ratio 0.67±0.23, <i>p</i>=0.002). The average Vancouver scar scale measured at the latest follow-up visit at least 6 months postoperatively was 1.62, and the risk of hypertrophic scarring was 8.6%. There was no significant difference in the Vancouver scar scale and the risk of hypertrophic scarring between the different surgical method groups.</p><p><strong>Conclusion: </strong>Purse-string sutures can be utilized in many stages of reconstruction to effectively reduce scar size without compromising the final cosmetic outcome.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"100-106"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/ae/ad-35-100.PMC10112374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant Cellulitis-like Sweet Syndrome Following Varicose Vein Surgery: A Rare Variant of Sweet Syndrome Mimicking Cellulitis.","authors":"Kyung-Nam Bae,&nbsp;Kihyuk Shin,&nbsp;Hoon-Soo Kim,&nbsp;Hyun-Chang Ko,&nbsp;Byung-Soo Kim,&nbsp;Moon-Bum Kim","doi":"10.5021/ad.20.129","DOIUrl":"https://doi.org/10.5021/ad.20.129","url":null,"abstract":"<p><p>Giant cellulitis-like Sweet syndrome (GCS) is the most recently defined variant of Sweet syndrome (SS) which could clinically mimic wide-spreading cellulitis. Although there has been only paucity of reports in the literature, it mostly appears at lower half of the body and histologically shows dense infiltration of neutrophils with occasional histiocytoid mononuclear cells. Although its exact etiology has not been clarified, abnormal conditions (e.g., infection, malignancy and drugs) could be related triggering factors and trauma itself can be one of the causative elements as a 'pathergy phenomenon'. GCS could be confusing manifestation especially when appeared in postoperative condition. A 69-year-old female presented with an erythematous edematous papules and plaques on the right thigh after varicose vein surgery. Skin biopsy revealed diffuse neutrophilic infiltrates that was consistent with SS. To our knowledge, there has been no report of GCS as a postoperative complication after varicose vein surgery. Physicians should be aware of this uncommon reactive neutrophilic dermatoses mimicking infectious cutaneous disease.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 2","pages":"151-154"},"PeriodicalIF":1.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/97/ad-35-151.PMC10112369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9330461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}